These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 27781421)
1. Pharmacokinetics and food-effect of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, in healthy adult Caucasian and Japanese subjects . Miyoshi S; Hey-Hadavi J; Nagaoka M; Tammara B Int J Clin Pharmacol Ther; 2016 Dec; 54(12):966-976. PubMed ID: 27781421 [TBL] [Abstract][Full Text] [Related]
2. Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study. Stock T; Fleishaker D; Wang X; Mukherjee A; Mebus C Int J Rheum Dis; 2017 Aug; 20(8):960-970. PubMed ID: 28328159 [TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis. Weatherley B; McFadyen L; Tammara B Clin Transl Sci; 2018 Jan; 11(1):54-62. PubMed ID: 29106053 [TBL] [Abstract][Full Text] [Related]
4. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. Buttgereit F; Strand V; Lee EB; Simon-Campos A; McCabe D; Genet A; Tammara B; Rojo R; Hey-Hadavi J RMD Open; 2019; 5(1):e000889. PubMed ID: 31168411 [TBL] [Abstract][Full Text] [Related]
5. Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics. Shoji S; Suzuki A; Conrado DJ; Peterson MC; Hey-Hadavi J; McCabe D; Rojo R; Tammara BK CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):439-448. PubMed ID: 28556506 [TBL] [Abstract][Full Text] [Related]
6. In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor. Ripp SL; Mukherjee A; Eng H; Stock T; Fleishaker D; Checchio T; Tammara B Clin Pharmacol Drug Dev; 2018 Mar; 7(3):244-255. PubMed ID: 29112329 [TBL] [Abstract][Full Text] [Related]
7. Renal and Hematologic Comparative Effects of Dissociated Agonist of the Glucocorticoid Receptor and Prednisone in Dogs With and Without Food Restriction. Radi ZA; Vogel WM; LaBranche T; Dybowski JA; Peraza MA; Portugal SS; Lettiere DJ Int J Toxicol; 2018; 37(3):223-233. PubMed ID: 29554821 [TBL] [Abstract][Full Text] [Related]
8. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326 [TBL] [Abstract][Full Text] [Related]
9. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. Taylor L; Gidal B; Blakey G; Tayo B; Morrison G CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683 [TBL] [Abstract][Full Text] [Related]
10. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects. Chen R; Shen K; Chang X; Tanaka T; Li L; Hu P Clin Ther; 2016 Aug; 38(8):1869-79. PubMed ID: 27461846 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837 [TBL] [Abstract][Full Text] [Related]
13. Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose-response analysis. Conrado DJ; Krishnaswami S; Shoji S; Kolluri S; Hey-Hadavi J; McCabe D; Rojo R; Tammara BK J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):325-41. PubMed ID: 27178257 [TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study. Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008 [TBL] [Abstract][Full Text] [Related]
15. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects. Bhattacharya I; Tarabar S; Liang Y; Pradhan V; Owens J; Oemar B Clin Ther; 2016 Jun; 38(6):1401-1416. PubMed ID: 27085586 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Flanagan SD; Bien PA; Muñoz KA; Minassian SL; Prokocimer PG Pharmacotherapy; 2014 Mar; 34(3):240-50. PubMed ID: 23926058 [TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers. Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. Peeva E; Hodge MR; Kieras E; Vazquez ML; Goteti K; Tarabar SG; Alvey CW; Banfield C Br J Clin Pharmacol; 2018 Aug; 84(8):1776-1788. PubMed ID: 29672897 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects. Shibata M; Hatta T; Saito M; Toyoshima J; Kaneko Y; Oda K; Nishimura T Clin Drug Investig; 2020 May; 40(5):469-484. PubMed ID: 32274653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]